 Continuous intra-arterial administration recombinant low-stage bladder cancer phase IB study Toxicity clinical effects intra-arterial IA continuous infusion recombinant twelve patients low-stage transitional cell carcinoma TCC bladder dosages groups patients courses interval evaluation clinical response transurethral resection TUR World Health Organization WHO toxicity patients hypotension/mental confusion fever side effects infusion laboratory toxicity patient proven complete responses CR partial responses PR patients patient overall response rate objective responses mean follow-up time months range months Local relapses months TUR nonresponders